Diagnostic test for thrombotic or thromboembolic disease
AssigneeThe Regents of the University of California
InventorTimothy A. Morris
Life of this patent
Estimating the term…
Abstract
Thrombotic or thromboembolic disease is detected or monitored by determining the presence or amount B in a urine sample.
Claims23
A method for detecting thrombotic or thromboembolic diseases in a patient comprising detecting a presence or amount of Fibrinopeptide B (FPB) and/or des-arginine FPB peptides in a sample of urine from the patient to determine whether the patient has thrombotic or thromboembolic disease.
A method of monitoring treatment of thrombotic or thromboembolic diseases in a patient comprising measuring a Fibrinopeptide B (FPB) and/or des-arginine FPB peptides level in a sample of urine from the patient and determining the level is significantly greater than in a normal population to determine whether the patient has thrombotic or thromboembolic disease.
A method for monitoring treatment of thrombotic or thromboembolic disease caused by a thrombosis or embolism in a patient comprising:
- (a) detecting an amount of Fibrinopeptide B (FPB) peptide present in a sample of urine obtained from the patient at a first time;
- (b) detecting an amount of FPB peptide present in a second sample of urine obtained from the patient at a second later time;
- and
- (c) comparing the amounts determined in steps (a) and (b) to determine whether the thrombosis or embolism is diminishing in size.
A diagnostic method for detecting thrombotic or thromboembolic disease in a patient comprising:
- (a) contacting a urine sample from the patient, the sample suspected of containing a presence or amount of fibrinopeptide B (FPB) peptide and/or des-arginine FPB peptide, with an amount of detection agent specific for FPB and/or des-arginine FPB peptides to form an FPB:
- detection agent complex;
- and
- (b) detecting the presence or amount of FPB and/or des-arginine FPB peptides in the sample to determine whether the patient has thrombotic or thromboembolic disease.
A diagnostic method for monitoring treatment of thrombotic or thromboembolic disease in a patient comprising:
- (a) contacting a urine sample suspected of containing fibrinopeptide B (FFB) peptide and/or des-arginine FPB peptide with an amount of detection agent specific for FPB and/or des-arginine FPB peptides to form an FPB:detection agent complex, wherein the sample is from a patient undergoing treatment for thrombotic or thromboembolic disease;
- and
- (b) detecting a presence or amount of FPB and/or des-arginine FPB peptides in the sample to monitor changes in the presence or amount of FPB and/or des-arginine FPB peptides in the patient to monitor treatment of the patient for thrombotic or thromboembolic disease.
Dependencies are inferred from the claim text.